Erasca · pitchdeck
Erasca | Investor Presentation Deck | 56 slides
56 pages · 4 arc beats · 2 loops
Erasca | Investor Presentation Deck | 56 slides
Erasca · 2023-11 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
12468101214161820222426283032343638404244464850525456
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 44 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Introduction to Erasca and RAS/MAPK pathway 5 slides 100% 5/5 slides 100% 5/5 slides · 25 hits — 0/5 slides
60% 3/5 slides · 4 hits 40% 2/5 slides 100% 5/5 slides 20% 1/5 slides Challenges in current cancer treatment and unmet needs 10 slides 100% 10/10 slides 100% 10/10 slides · 47 hits — 0/10 slides
60% 6/10 slides 30% 3/10 slides 100% 10/10 slides 60% 6/10 slides Erasca's pipeline and clinical data 27 slides 100% 27/27 slides 100% 27/27 slides · 119 hits — 0/27 slides
44.4% 12/27 slides 29.6% 8/27 slides 100% 27/27 slides 18.5% 5/27 slides Potential impact and investment thesis 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits — 0/2 slides
100% 2/2 slides — 0/2 slides
100% 2/2 slides — 0/2 slides
Slide inventory
56 every slide · same image gating as the playbook
01
The slide uses a high-quality lifestyle photo to establish an emotional connection to the company's mission.front_matter
Open slide detailBeat · Introduction to Erasca and RAS/MAPK pathway
03
The slide uses a hub-and-spoke diagram to connect the company name to three core pillars: leadership, portfolio, and financials.inspire_vision
Open slide detailBeat · Introduction to Erasca and RAS/MAPK pathway
04
SAB stands for Scientific Advisory Board.other
Open slide detailBeat · Introduction to Erasca and RAS/MAPK pathway
05
The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.size_opportunity
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for the company's therapeutic approach.present_solution
07
The slide uses a Gantt-style visualization for clinical trial progress.plan_implementation
08
The slide uses a biological process diagram to map drug assets to specific protein targets.present_solution
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collacompare_peers
10
The chart uses a stacked bar approach to represent US and Europe patient counts per program, with a total sum at the bottom.size_opportunity
11
The slide combines a biological pathway diagram (left) with a quantitative market sizing table (right).size_opportunity
Open slide detailBeat · Challenges in current cancer treatment and unmet needs
12
The kinome tree is a standard visualization for kinase selectivity.present_solution
Open slide detailBeat · Challenges in current cancer treatment and unmet needs
13
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate proof of concept.show_traction
Open slide detailBeat · Challenges in current cancer treatment and unmet needs
14
Includes two waterfall plots comparing patient responses; source cited as Novartis materials.show_traction
Open slide detailBeat · Challenges in current cancer treatment and unmet needs
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.frame_problem
Open slide detailBeat · Challenges in current cancer treatment and unmet needsLoop · Cost Of Inaction
16
Waterfall plot shows individual patient responses; table compares efficacy metrics against Dacarbazine and Binimetinib.show_traction
17
The slide uses a before-after-framing approach to demonstrate clinical efficacy.illustrate_case
18
The slide uses a swimmer plot to visualize individual patient treatment duration and response status.show_traction
19
The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.show_traction
20
Swimmer plot showing individual patient treatment duration and response status (NE, PD, PR, SD).show_traction
21
The diagram uses a flow-chart structure to categorize patient outcomes (off treatment vs on treatment) and further breaks down the 'on treatment' group into SDsshow_traction
Open slide detailBeat · Erasca's pipeline and clinical data
22
The chart displays adverse events occurring in >=10% of patients (n=15).analyze_data
Open slide detailBeat · Erasca's pipeline and clinical data
23
CoC = Cost of Care (or standard of care context); FIH = First-in-Human; PTS = Probability of Technical Success; CDP = Clinical Development Plan.plan_implementation
Open slide detailBeat · Erasca's pipeline and clinical data
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.present_solution
Open slide detailBeat · Erasca's pipeline and clinical data
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.size_opportunity
Open slide detailBeat · Erasca's pipeline and clinical data
26
The slide uses two tables to demonstrate competitive advantage in potency and pharmacokinetics.present_solution
Open slide detailBeat · Erasca's pipeline and clinical data
27
The diagram shows the signaling pathway with specific drug targets highlighted.present_solution
Open slide detailBeat · Erasca's pipeline and clinical data
28
The slide compares tumor volume reduction across two different CDX models (WiDr and RKO) using various treatment regimens.show_traction
Open slide detailBeat · Erasca's pipeline and clinical data
29
Includes waterfall plot and swimmer plot for clinical trial results.show_traction
Open slide detailBeat · Erasca's pipeline and clinical data
30
Data cut 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.analyze_data
Open slide detailBeat · Erasca's pipeline and clinical data
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.show_traction
Open slide detailBeat · Erasca's pipeline and clinical data
32
The slide highlights selectivity and potency, using arrows to indicate performance relative to the competitor.compare_peers
Open slide detailBeat · Erasca's pipeline and clinical data
33
Data presented as tumor volume over time (days) with error bars representing SEM.show_traction
Open slide detailBeat · Erasca's pipeline and clinical data
34
Includes RECIST 1.1 criteria reference and specific patient history.illustrate_case
Open slide detailBeat · Erasca's pipeline and clinical data
35
The table compares 'ALL' vs 'Gr >= 3' adverse events for different dosing regimens.analyze_data
Open slide detailBeat · Erasca's pipeline and clinical data
36
The diagram shows the EGFR signaling pathway and the inhibitory effect of ERAS-801.size_opportunity
Open slide detailBeat · Erasca's pipeline and clinical data
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to contrast clinical outcomes across different indications.frame_problem
Open slide detailBeat · Erasca's pipeline and clinical data
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.present_solution
Open slide detailBeat · Erasca's pipeline and clinical data
39
The chart is a Kaplan-Meier survival plot. The comparison shows ERAS-801 (blue line) outperforming standard EGFR inhibitors (Erlotinib, Lapatinib, Osimertinib) present_solution
Open slide detailBeat · Erasca's pipeline and clinical data
40
The slide displays four distinct survival plots (HK301, GS025, HK336, GS187) showing statistically significant survival improvements (***) with ERAS-801 treatmeshow_traction
Open slide detailBeat · Erasca's pipeline and clinical data
41
The slide uses a waterfall plot to show individual model responses and pie charts to summarize efficacy across the total cohort vs. the specific EGFR-mutant/ampshow_traction
Open slide detailBeat · Erasca's pipeline and clinical data
42
The slide uses a table format to communicate a product roadmap for clinical development.plan_implementation
Open slide detailBeat · Erasca's pipeline and clinical data
44
Features the Erasca logo and a Lorenz attractor-style graphic.summarize
Open slide detailBeat · Potential impact and investment thesis
45
The slide uses a matrix-like layout to compare drug candidates by development stage and company, with a callout box for competitive advantages.compare_peers
46
The slide uses a bullseye/concentric circle framework to communicate strategic prioritization of clinical trials.prioritize
47
The slide uses a contrast-based layout to frame the subject as a winner in a difficult therapeutic space.compare_peers
48
The slide uses western blot data to demonstrate the superiority of ERAS-007 in a specific biological pathway context.present_solution
49
Includes RECIST 1.1 criteria reference and patient progression note.illustrate_case
50
The chart displays individual patient responses to treatment, with bars colored by dosage level.show_traction
51
The chart displays individual patient treatment timelines, with markers for partial response, stable disease, and progressive disease.show_traction
53
The slide uses a line chart to show concentration over time and a table to summarize key PK metrics (Cmax, Cmin, T>IC90, T<IC50) for five different dosing regimanalyze_data
54
The slide uses a comparative layout contrasting a list of competitor assets with the specific benefits of the company's own asset (ERAS-601).compare_peers
55
The slide uses a biological pathway diagram to illustrate the mechanism of action.present_solution
56
The slide contrasts intermittent high-coverage dosing (ERAS-007) with sustained steady-state coverage (ERAS-601) to manage efficacy vs. toxicity.present_solution